Resumen

NAVARRO-ROA, Cassandra; RODRIGUEZ-VIOLANTE, Mayela  y  CERVANTES-ARRIAGA, Amin. Título en inglés: Infusion therapies in advanced Parkinson's disease. Rev. mex. neurocienc. [online]. 2019, vol.20, n.1, pp.3-13.  Epub 04-Abr-2022. ISSN 2604-6180.  https://doi.org/10.24875/rmn.m19000018.

Parkinson's disease (PD) is a neurodegenerative disorder whose treatment is symptomatic, usually initiated as monotherapy, but with the progression of symptoms and the appearance of motor complications the use of polytherapy is frequent. The patient with advanced disease with an inadequate response to treatment with oral or transdermal drugs may be a candidate for device-assisted therapies such as deep brain stimulation, continuous subcutaneous apomorphine infusion (CSAI) and levodopa/carbidopa intestinal gel (LCIG). The last two treatments also receive the denomination of infusion therapies. The present review has the objective of presenting the historical background, pharmacological characteristics, indications, contraindications, initiation and dosage, effectivity on motor and non-motor symptoms, safety profile and selection of the ideal candidate for CSAI and LCIG therapies for patients with advanced PD.

Palabras llave : Advanced Parkinson's disease; Device-assisted therapy; Infusion therapy; Continuous subcutaneous apomorphine infusion; Levodopa/carbidopa intestinal gel.

        · resumen en Español     · texto en Español     · Español ( pdf )